The stock has more than doubled in twelve months on a deal the DOJ just slowed down.

• The deal. All-stock Valaris combination announced Feb 9 (15.235 RIG per VAL share); pro-forma ~73-rig combined fleet, ~$17B EV, $200M+ run-rate synergy target, 1.5x net leverage target within 24 months of close.
• The clock just stretched. DOJ issued a Second Request on May 4 extending the HSR waiting period until 30 days after substantial compliance; outside dates run to Feb 9, 2027 (base) and Aug 9, 2027 (final). Angola, Australia, Brazil, and Egypt clearances still pending.
• The asymmetric tail. Conduct-only remedies preserve the scale-leader frame and validate a peer-multiple comparison against Noble (9.4x EV/EBITDA). A structural rig-divestiture demand or a block re-exposes $5.0B of net debt on a CCC+ standalone driller — the bear-case $3 downside.

Already-signed UDW dayrates step from $461K to $635K through 2030 on a fleet no one will rebuild this decade.

• The ladder is contracted, not forecast. Average ultra-deepwater backlog dayrate climbs from $461K (2026) to $488K (2028) to $635K (2030) per the FY2025 10-K; Q1 2026 fleet average daily revenue of $475.6K was the highest in years.
• Supply discipline is the load-bearing assumption. No newbuild floater orders industry-wide since ~2014; reactivating a cold-stacked drillship now costs roughly $100M–$150M and 12–15 months. Capital markets remain effectively closed to speculative fossil-fuel rigs.
• Replacement value gap. 27 rigs at conservative replacement cost is $13B–$20B versus $9.1B EV today; the Atlas and Titan drillships alone cost ~$2.25B to build. Every year no Korean order lands, the option value compounds.

Revenue recovered 55% in four years, debt fell $2.8B from the FY2018 peak, and the share count tripled.

• The pattern. Diluted share count rose from 364M in FY2015 to 1,102M in FY2025 — roughly 12%/year dilution across the decade. Every cyclical equity issuance — to defease debt, fund the Liquila/Orion roll-ins, bridge the September 2025 raise — landed at a trough price.
• Why it keeps happening. A CCC+ credit rating and $5.04B of net debt against $620M of cash mean each cyclical drag has been backstopped with fresh equity rather than refinancing. The September 2025 raise alone added 144M shares; FY2025 net equity issuance was $421M.
• Why it is the deck's punchline. Sell-side bull ($11–$13) and bear ($3–$4.50) targets both default to a static ~1.1B share count. Neither prices another impairment-and-issuance cycle. Whether the share count flattens through the next downturn is the single test the prior decade failed.

FY2025's $626M free cash flow came with capex at 0.19x depreciation — the lowest reading in the dataset.

• Three impairments on the same asset group. $57M (FY23) to $772M (FY24) to $3.05B (FY25), with Discoverer Inspiration and Development Driller III impaired in FY24 then re-impaired in FY25. A securities class action (Gábor v. Transocean, S.D.N.Y. 24-cv-09964) alleges carrying values were known to be overstated during a May 2023–Sep 2024 class period.
• Capex collapsed in the year before a stock-for-stock merger. $123M against $659M of depreciation. FY2026 management guidance is ~$150M. If maintenance capex normalizes toward a $250M run-rate, roughly $100M+ of FCF would disappear mechanically.
• The bonus paid above target on the cleaned-up number. Adjusted Net Income of +$37M sits beside a GAAP loss of $2.9B; the comp formula excludes impairments and the equity-raise dilution. The FY2026 10-K's held-for-sale impairment line on the residual fleet is the next clean test.

The cash engine retired $1.26B of principal in 2025 — but ROIC has been negative for nine straight years.

Revenue has compounded for four straight years off a $2.56B trough and gross margin widened to 39% as dayrates outran operating-cost inflation. The equity sits on a CCC+ credit, ROIC has been negative since FY2017, and the FY2025 impairments removed $2.18B of book value in a single year. Net leverage needs another full cash-flow cycle to fall toward management's 1.5x post-Valaris target and reopen lower-cost financing.